Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Boan Biotechnology Co has the GF Score of 39, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Shandong Boan Biotechnology Co
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Shandong Boan Biotechnology Co (FRA:UJ9) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Shandong Boan Biotechnology Co GF Score Related Terms
FRA:UJ9 vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's GF Score distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's GF Score falls into.
Shandong Boan Biotechnology Co (FRA:UJ9) has a GF Score of 39 as of Jul. 17, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Shandong Boan Biotechnology Co and its competitors. This is 129% above median its historical median of 17.00. Over the past decade, Shandong Boan Biotechnology Co's GF Score has ranged from 4.00 to 46.00.
Is Shandong Boan Biotechnology Co's GF Score too high?
Shandong Boan Biotechnology Co's current GF Score of 39 is 129% above median its 10-year median of 17.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 46.00. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's GF Score compare to VRTX and REGN?
Shandong Boan Biotechnology Co's GF Score of 39 can be compared against companies in the Biotechnology industry. Historically, Shandong Boan Biotechnology Co's own GF Score has ranged from 4.00 to 46.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current GF Score is 39, which is 129% above median its own 10-year median of 17.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current GF Score of 39. The stock's GF Value™ is €1.72, compared to a current price of €0.61 — trading 64.8% below its estimated fair value. The current GF Score is 39, which is 129% above median its 10-year median of 17.00. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current GF Score is 39 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.61 is trading 64.8% below its estimated GF Value™ of €1.72.
Key valuation signals for FRA:UJ9:
GF Score: 39 (129% above median its 10-year median of 17.00)
GF Value™: €1.72 vs. price of €0.61 (64.8% below fair value)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score
Get the complete analysis for FRA:UJ9
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
